$RXRX earnings report

Recursion reported third-quarter revenue of $18.6 million, reduced net loss and operating cash use, extended its cash runway into 2029, and reported positive REC-4881 and REC-1245 clinical updates. AlphAI read Recursion Pharmaceuticals's third quarter of 2026 filing as solid. 3 quarters are on record below.

third quarter of 2026

AlphAI · Earnings readRXRX · third quarter of 2026 · ended September 30, 2026

Recursion reported third-quarter revenue of $18.6 million, reduced net loss and operating cash use, extended its cash runway into 2029, and reported positive REC-4881 and REC-1245 clinical updates.

✓Solid quarter

Revenue increased to $18.6 million, supported by a $10.0 million Sanofi milestone, while research and development expense, general and administrative expense, net loss and operating cash use declined. The company also reported approximately $748.7 million of pro forma cash and reiterated 2026 cash operating expense guidance while introducing lower 2027 guidance.

Revenue
$18.6M
EPS · GAAP
$ (0.22)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, three months ended September 30GAAP$18.55M––
Operating revenue, three months ended September 30GAAP$18.05M––
Grant revenue, three months ended September 30GAAP497K––
Cost of revenue, three months ended September 30GAAP10.04M––
Research and development expense, three months ended September 30GAAP$99.1M––
General and administrative expense, three months ended September 30GAAP$32.6M––
Total operating costs and expenses, three months ended September 30GAAP141.7M––
Loss from operations, three months ended September 30GAAP−123.2M––
Other income, net, three months ended September 30GAAP4.17M––
Loss before income taxes, three months ended September 30GAAP−119.0M––
Income tax benefit (expense), three months ended September 30GAAP−25K––
Net loss, three months ended September 30GAAP−$119.0M––
Net loss per share of Class A, B and Exchangeable common stock, basic and diluted, three months ended September 30GAAP$ (0.22)––
Weighted-average shares (Class A, B and Exchangeable) outstanding, basic and diluted, three months ended September 30GAAP543,000,977––
Total revenue, nine months ended September 30GAAP32.69M––
Operating revenue, nine months ended September 30GAAP31.66M––
Grant revenue, nine months ended September 30GAAP1.03M––
Cost of revenue, nine months ended September 30GAAP34.03M––
Research and development expense, nine months ended September 30GAAP276.6M––
General and administrative expense, nine months ended September 30GAAP108.7M––
Total operating costs and expenses, nine months ended September 30GAAP419.3M––
Loss from operations, nine months ended September 30GAAP−386.6M––
Net loss, nine months ended September 30GAAP−$367.5M––
Net loss per share of Class A, B and Exchangeable common stock, basic and diluted, nine months ended September 30GAAP$ (0.69)––
Net cash used in operating activities, three months ended September 30GAAP−$77.41M––
Net cash used in operating activities, nine months ended September 30GAAP−$264.5M––
Net cash used in investing activities, three months ended September 30GAAP−407K––
Net cash used in investing activities, nine months ended September 30GAAP−2.70M––
Net cash provided by financing activities, three months ended September 30GAAP83.14M––
Net cash provided by financing activities, nine months ended September 30GAAP78.41M––
Cash operating expense, nine months ended September 30non-GAAP$271.5M––

2026 and 2027 outlook

  • Note2026 cash operating expense guidance reiterated at less than $375 million
  • Note2027 guidance of less than $360 million
  • NoteBased on current operating plans with no additional financing, the Company expects its cash runway to extend into 2029.
  • NoteThe Company anticipates initiating a registrational trial in the second half of 2027, pending ongoing FDA discussions.
  • NotePreliminary dose expansion data in endometrial cancer are expected in the second half of 2027.
  • NotePhase 1 clinical study expected to begin in 2027.

What drove it

  • The increase in total revenue was driven primarily by the Company's collaboration with Sanofi, under which the Company achieved a $10.0 million milestone for an immunology small molecule program during the quarter.
  • The decline in research and development expense was driven primarily by $22.8 million of in-process research and development costs related to the acquisition of full rights to REC-102 in the third quarter of 2025 that did not recur in the current period.
  • The decrease in general and administrative expense was primarily driven by a decrease in infrastructure technology expenses and professional service costs.
  • The decrease in cash used in operating activities was primarily driven by operating efficiencies across the company and working capital movements.
  • Sanofi's option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments achieved from Sanofi under the collaboration to $144 million.

Concerns

  • The company reported a net loss of $119.0 million for the third quarter of 2026.
  • Total revenue consists primarily of revenue from collaboration agreements.
  • REC-4881 registrational trial initiation is pending ongoing FDA discussions.
  • REC-1245 data are from the Phase 1 dose-escalation portion of DAHLIA, and dose escalation will continue in other solid tumor indications.
  • The company stated that interim, preliminary, or topline clinical data may change as more patient data become available and may not be predictive of final results.

What to watch

  • Additional REC-4881 registrational-trial details, which the company said it will provide later this year.
  • Initiation of the REC-4881 registrational trial in the second half of 2027, pending ongoing FDA discussions.
  • Preliminary REC-1245 dose-expansion data in endometrial cancer expected in the second half of 2027.
  • Sanofi's expected Phase 1 clinical study in 2027 for the optioned immunology development candidate.
  • Potential additional Sanofi development-candidate and late-stage discovery milestones over the next 12 months.
  • Cash operating expense relative to guidance of less than $375 million for 2026 and less than $360 million for 2027.

Balance sheet and cash flow

  • Cash, cash equivalents and restricted cash were $561.5 million as of September 30, 2026.
  • Cash and cash equivalents were $ 549,853 (in thousands) as of September 30, 2026, compared to $ 743,294 (in thousands) as of December 31, 2025.
  • Restricted cash was 6,657 (in thousands) as of September 30, 2026, compared to 4,594 (in thousands) as of December 31, 2025.
  • Restricted cash, non-current was 5,020 (in thousands) as of September 30, 2026, compared to 6,033 (in thousands) as of December 31, 2025.
  • Including net proceeds of approximately $187.2 million from the Company's underwritten offering which completed on October 16, 2026, pro forma cash, cash equivalents and restricted cash were approximately $748.7 million.
  • Notes payable and financing lease liabilities were 11,808 (in thousands) current and 93 (in thousands) non-current as of September 30, 2026.
  • Net cash used in operating activities was $77.4 million for the three months ended September 30, 2026, compared to net cash used in operating activities of $117.4 million for the three months ended September 30, 2025.
  • Cash, cash equivalents and restricted cash, end of period were $ 561,530 (in thousands) for the three months and nine months ended September 30, 2026.

Analysis

Third-quarter revenue was $18.6 million, compared to $5.2 million in the third quarter of 2025. The release attributed the increase primarily to a $10.0 million Sanofi milestone for an immunology small molecule program. Operating revenue was $ 18,055 (in thousands), while grant revenue was 497 (in thousands). For the nine months ended September 30, total revenue was 32,694 (in thousands), compared with 39,143 (in thousands) in the prior-year period, showing that the quarterly milestone did not offset lower year-to-date revenue.

The cost base declined across major operating lines. Research and development expense was $99.1 million, compared with $121.1 million, principally because $22.8 million of REC-102 in-process research and development costs recognized in the third quarter of 2025 did not recur. General and administrative expense was $32.6 million, compared with $41.6 million, due primarily to lower infrastructure technology expense and professional-service costs. Loss from operations was (123,176) (in thousands) and net loss was $ (119,036) (in thousands), compared with $ (162,253) (in thousands) a year earlier.

Liquidity improved following the October financing. Cash, cash equivalents and restricted cash were $561.5 million as of September 30, 2026, and pro forma cash, cash equivalents and restricted cash were approximately $748.7 million after approximately $187.2 million in net proceeds from the October 16, 2026 underwritten offering. Net cash used in operating activities was $77.4 million for the quarter, compared with $117.4 million in the prior-year quarter. Nine-month cash operating expense was $271.5 million, compared with $323.2 million, and management expects cash runway to extend into 2029 based on current operating plans with no additional financing.

The clinical and partnership updates were central to the release. In REC-4881, 87% of patients had a reduction in total polyp burden after 12 weeks of treatment, with a 47% median reduction, and 85% of evaluable patients remained below baseline 12 weeks after stopping treatment. REC-1245 produced three partial responses per RECIST 1.1 criteria, including 2 confirmed and 1 unconfirmed, at doses of 45 mg once daily or higher, with a 91.7% disease control rate at those doses. Sanofi's option of a development candidate generated a $10 million milestone, while Recursion plans to focus resources on selected internal programs and high-impact partnerships.

The company reiterated 2026 cash operating expense guidance of less than $375 million and issued 2027 cash operating expense guidance of less than $360 million. Operational milestones to follow include additional REC-4881 registrational-trial detail later this year, an anticipated REC-4881 registrational-trial initiation in the second half of 2027 pending FDA discussions, preliminary REC-1245 endometrial-cancer expansion data in the second half of 2027, and the expected start of Sanofi's Phase 1 study in 2027.

Management, verbatim

To pioneer a new blueprint for making medicines with AI, we believe you have to tie together three core capabilities in one engine: uncover novel biology, design differentiated molecules against challenging targets, and generate clinical evidence that matters for patients. The new TUPELO data are important clinical evidence, with REC-4881 showing deep polyp burden reductions across the upper and lower GI tract, including larger, higher-risk polyps, and reductions that persist after treatment stops. REC-1245 is an encouraging early example of that engine coming together within a single program, from biological insight surfaced by our platform to molecule design and now early clinical signals in heavily pretreated patients.

Najat Khan, Ph.D., President and Chief Executive Officer of Recursion

Beyond our own pipeline, Sanofi has optioned a potential first-in-class molecule against a challenging dual target, while Genentech has advanced an unexplored neuroscience target from our maps. These are different programs, but they are outputs of the same AI-native engine, providing evidence of repeatability. We will keep concentrating capital where the evidence is strongest and turning innovation into impact for patients who are waiting.

Najat Khan, Ph.D., President and Chief Executive Officer of Recursion

Not in the filing

stated, not guessed
  • GAAP gross profit and gross margin
  • non-GAAP net income or loss
  • non-GAAP earnings per share
  • free cash flow
  • dividends
  • share repurchases
  • prior-quarter comparisons for reported operating metrics
  • revenue guidance
  • gross margin guidance
  • tax rate guidance
  • The previous outlook covered the full year 2026 only, and this quarterly release has no guidance for the third quarter to compare against.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

third quarter of 2026

AlphAI · Earnings readRXRX · third quarter of 2026

Sanofi optioned the first development candidate from its collaboration with Recursion, triggering a $10 million milestone payment to be recognized as revenue in the third quarter of 2026.

✓Solid quarter

The filing reports a meaningful collaboration milestone, revenue recognition of a $10 million payment in the third quarter of 2026, and transfer of further development and commercialization responsibility to Sanofi. It does not provide a complete quarterly financial-results release.

Revenue
$10M

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Sanofi option milestone paymentother$10M––
Milestone payment to be recognized as revenue in the third quarter of 2026other$10M––
Total upfront and milestone payments received from Sanofi under the collaborationother$144M––
Additional potential milestones for the optioned programothermore than $300 million––
Progress-based milestones achieved across the Recursion-Sanofi collaborationothersix progress-based milestones across five programs––

2027 and over the next 12 months outlook

  • NoteThe candidate is expected to enter phase 1 clinical trials in 2027.
  • NoteOver the next 12 months, other programs in the joint portfolio have the potential to reach development candidate and other progress-based milestones.

What drove it

  • Sanofi optioned the first development candidate from the companies’ multi-program research collaboration.
  • The potential first-in-class oral small molecule was designed against a challenging dual target implicated in inflammatory disease.
  • The candidate was delivered through Recursion’s integrated AI-enabled drug design platform and small-molecule chemistry capabilities combined with Sanofi’s drug-discovery and immunology expertise.
  • Sanofi will fund and lead further development and commercialization of the optioned candidate.
  • The option ends Recursion’s operational requirements related to this candidate, with all future payments resulting in profit to Recursion.

Concerns

  • The candidate is expected to enter phase 1 clinical trials in 2027 and remains subject to clinical-development, safety, efficacy, regulatory, and commercialization risks.
  • Sanofi retains discretion over option exercises, program advancement, and funding and may delay, deprioritize, or discontinue development of the optioned candidate.
  • More than $300 million in additional milestones and royalties are contingent on future program progress and successful commercialization.
  • The filing contains no complete income statement, cash flow statement, balance sheet, or quarterly operating-expense disclosure.

What to watch

  • Recognition of the $10 million milestone payment as revenue in the third quarter of 2026.
  • Initiation of the optioned candidate’s planned phase 1 clinical study in 2027.
  • Potential development-candidate and other progress-based milestones from additional programs in the joint portfolio over the next 12 months.
  • Sanofi’s continued funding and advancement of the optioned program.

Balance sheet and cash flow

  • The $10 million milestone payment will be recognized as revenue in the third quarter of 2026.
  • Sanofi’s selection of the development candidate triggered a $10 million milestone payment to Recursion.

Analysis

This Item 2.02 filing is a collaboration-development update rather than a complete quarterly earnings release. Sanofi optioned the first development candidate from the companies’ multi-program research collaboration, triggering a $10 million milestone payment. Recursion states that this payment will be recognized as revenue in the third quarter of 2026, but the filing does not report total third-quarter revenue or any other complete quarterly financial results.

The option raises total upfront and milestone payments received from Sanofi under the collaboration to $144 million. The companies have achieved six progress-based milestones across five programs. Recursion remains eligible for more than $300 million in additional milestones for the optioned program, along with an average of low double-digit royalties on net product sales if it is successfully commercialized.

The operational structure changes favorably for Recursion on the optioned program: Sanofi will fund and lead further development and commercialization, while the option ends Recursion’s operational requirements related to this candidate. Recursion states that all future payments related to the candidate will result in profit to Recursion. The candidate has been added to Sanofi’s development pipeline and is expected to enter phase 1 clinical trials in 2027.

The milestone supports the stated utility of Recursion’s platform in progressing a complex dual-target small-molecule design program. The company attributes delivery of the candidate to iterative computational prediction, chemical design, synthesis, and experimental validation, combined with Sanofi’s drug-discovery and immunology expertise. The filing also identifies further potential milestone activity, stating that other joint-portfolio programs could reach development-candidate and other progress-based milestones over the next 12 months.

The principal limitation is that the filing provides no total revenue, expenses, profitability, cash balance, cash flow, or balance-sheet data for the third quarter of 2026. The future economic value remains contingent on development progress, clinical outcomes, regulatory approval, commercialization, and Sanofi’s decisions on funding and program prioritization.

Management, verbatim

The most important test of any technology platform in drug discovery is whether it can translate into differentiated medicines. Together with Sanofi, we tackled a difficult design problem against a dual target product profile with high potential and delivered a molecule that Sanofi has now selected for its development pipeline. With additional programs advancing across our collaboration, this milestone is another important demonstration of how our platform can translate computational capabilities into differentiated medicines — and do so repeatedly.

Najat Khan, Ph.D., President and Chief Executive Officer of Recursion

By combining Sanofi's drug discovery and clinical and translational knowledge in Immunology with Recursion's AI-driven platform, we were able to move with speed and precision in a space where that balance is notoriously hard to achieve. This new development candidate has potential to deliver a differentiated oral medicine with highly selective dual targeting that could be a meaningful advance for people living with inflammatory diseases who still lack adequate treatment options.

Alyssa Johnsen, Therapeutic Area Head, Development, Immunology & Inflammation, Sanofi

Not in the filing

stated, not guessed
  • Period-end date for the third quarter of 2026
  • Total revenue for the third quarter of 2026
  • Revenue comparison with the prior-year period
  • Revenue comparison with the prior quarter
  • Gross profit and gross margin
  • Operating expenses
  • Operating income or loss
  • Net income or loss
  • GAAP earnings or loss per share
  • Non-GAAP earnings or loss per share
  • Operating cash flow
  • Free cash flow
  • Cash and cash equivalents
  • Debt
  • Share repurchases
  • Dividends
  • Revenue, margin, operating-expense, or tax-rate financial guidance
  • The previous outlook covered the full year 2026 with no quarterly guidance, and this release reports only the third quarter, so there is nothing to compare.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readRXRX · Second Quarter 2026 · ended June 30, 2026

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

→Mixed quarter

Revenue was $7.7 million versus $19.2 million in the prior-year quarter, while research and development expenses decreased to $89.6 million from $128.6 million and 2026 cash operating expense guidance was reduced to <$375 million.

Revenue
$7.7M

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenueGAAP$7.7M––
Research and development expensesGAAP$89.6M––
Cash, cash equivalents and restricted cashother$556.8M––
Roche and Genentech collaboration upfront and milestone payments to dateother$216M––
Sanofi collaboration upfront and milestone payments to dateother$134M––

2026 outlook

  • Operating expenses<$375 million
  • NoteBased on current operating plans with no additional financing, the Company continues to expect its cash runway to extend into early 2028.

What drove it

  • Roche and Genentech revenue recognized was less in the current period due to the successful completion of certain project phases in the prior period.
  • Research and development expenses decreased primarily due to lower platform costs resulting from the timing of Tempus record purchases.
  • Genentech exercised the first Validated Target Option under the companies' neuroscience collaboration, advancing a previously unexplored neuroscience target into a small molecule early discovery program.
  • REC-7735 was precision designed to show >100-fold selectivity for the H1047R mutant over wild type.
  • The REC-7735 development candidate was delivered in 10 months and 242 compounds from first novel hit through Recursion's AI-native design platform.
  • Agent-supported enrollment strategies contributed to a 1.3 to 1.6x increase in enrollment rates versus historical benchmarks.

Concerns

  • Total revenue was $7.7 million for the second quarter of 2026, compared to $19.2 million for the second quarter of 2025.
  • Cash, cash equivalents and restricted cash were $556.8 million as of June 30, 2026 compared to $753.9 million as of December 31, 2025.
  • The supplied filing text ends during the explanation of research and development expenses, before the complete financial-results disclosure and financial statements.

What to watch

  • An update to define the registrational path for REC-4881 is expected in 2H26.
  • Additional Phase 2 safety and efficacy data from the TUPELO clinical trial will be presented in November 2026.
  • The Phase 1/2 ZINNIA clinical study for REC-7735 is expected to be initiated in the second half of 2026.
  • Additional Phase 1 dose escalation data for REC-1245 are expected in 2H26.
  • Potential differentiated AI-enabled oral molecules could reach development candidate and late-stage discovery milestones with Sanofi over the next 6-12 months.

Balance sheet and cash flow

  • Cash, cash equivalents and restricted cash were $556.8 million as of June 30, 2026 compared to $753.9 million as of December 31, 2025.
  • Based on current operating plans with no additional financing, the Company continues to expect its cash runway to extend into early 2028.

Analysis

Second-quarter revenue was $7.7 million, compared to $19.2 million in the second quarter of 2025. The company attributed lower Roche and Genentech revenue recognition to successful completion of certain project phases in the prior period. The result underscores that reported collaboration revenue can vary with the timing of project milestones and completion phases.

Research and development expenses decreased to $89.6 million from $128.6 million. Recursion cited lower platform costs resulting from the timing of Tempus record purchases as a primary driver. The company also reduced 2026 cash operating expense guidance to <$375 million from <$390 million, placing expense control alongside continued pipeline development.

Cash, cash equivalents and restricted cash were $556.8 million as of June 30, 2026, compared with $753.9 million as of December 31, 2025. Management stated that, based on current operating plans with no additional financing, its cash runway is expected to extend into early 2028. No operating cash flow, free cash flow, debt, repurchase, or dividend data were included in the supplied text.

Operationally, Genentech exercised the first Validated Target Option in the neuroscience collaboration and advanced a previously unexplored target into a small molecule early discovery program. Recursion also reported an IND clearance for REC-7735 and expects to initiate its Phase 1/2 ZINNIA study in the second half of 2026. Near-term execution points include the expected REC-4881 registrational-path update in 2H26, additional REC-4881 Phase 2 data in November 2026, REC-7735 trial initiation, and additional REC-1245 Phase 1 data in 2H26.

Management, verbatim

Recursion has reached a pivotal point where our AI-native platform is translating unique data into potential first-in-class therapeutic opportunities.

Najat Khan, Ph.D., Chief Executive Officer of Recursion

Not in the filing

stated, not guessed
  • Gross profit and gross margin
  • Selling, general and administrative expenses
  • Total operating expenses
  • GAAP operating income or loss
  • Non-GAAP operating income or loss
  • GAAP net income or loss
  • Non-GAAP net income or loss
  • GAAP earnings or loss per share
  • Non-GAAP earnings or loss per share
  • Weighted-average shares outstanding
  • Operating cash flow
  • Free cash flow
  • Debt balances
  • Share repurchases
  • Dividends
  • Revenue, gross margin, tax rate, and other financial guidance beyond 2026 cash operating expense guidance
  • Prior outlook document for guidance comparison
  • Complete remaining financial-results disclosure, as the supplied filing text ends mid-sentence

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about RXRX earnings dates

When is Recursion Pharmaceuticals's next earnings date?
AlphAI has no date for RXRX yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.